TRISENOX is indicated for induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.

For healthcare professionals or patients with specific medical questions about TRISENOX ®, please contact: Teva Medical Information. 1-888-4-TEVARX (1-888-483-8279) To request more information about TRISENOX, click here.

We are providing an update regarding the supply of TRISENOX ® (arsenic trioxide) Injection. Working with the U.S. Food and Drug Administration to a void a critical shortage and to assure uninterrupted supply of this life-saving medicine, Teva has decided to release the following TRISENOX Lots: 7B05125 7B05126 7B05127 7G04417 7G04418

TRISENOX is indicated for the induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or

2013年9月9日 · VISITORS TO WWW.TRISENOX.COM ARE URGED AND ADVISED TO SEEK THE ADVICE OF A PHYSICIAN BEFORE BEGINNING ANY TREATMENT. Such individuals are specifically warned to seek professional medical advice prior …

TRISENOX is an arsenical indicated: • In combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17)